IM-MV 24-020_000
|
Universitair Medisch Centrum Utrecht
|
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma
|
|
Ontwerpbesluit genomen
|